Close
Harel Dahari

Associate Professor

Education

Affiliations

Bio

Preferred Pronouns

Personal Academic Website

Research/Topics of Interest

Pathogens/Diseases of Main Interest/Expertise

Countries of Work/Collaboration

Projects

Papers

Boodram B, Mackesy-Amiti ME, Khanna A, Brickman B, Dahari H, Ozik J. (2022). People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination. PloS one, 17(1)

Tatara E, Gutfraind A, Collier NT, Echevarria D, Cotler SJ, Major ME, Ozik J, Dahari H, Boodram B. (2022). Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. PloS one, 17(3)

Shekhtman L, Cotler SJ, Ploss A, Dahari H. (2022). Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation. Journal of hepatology

Reinharz V, Churkin A, Dahari H, Barash D. (2022). Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics. Mathematics (Basel, Switzerland), 10(12)

Goyal A, Churkin A, Barash D, Cotler SJ, Shlomai A, Etzion O, Dahari H. (2022). Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration. Open forum infectious diseases, 9(5)

Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. (2021). Understanding hepatitis B virus dynamics and the antiviral effect of interferon-α treatment in humanized chimeric mice. Journal of virology

Bhutta MS, Sausen DG, Gallo ES, Dahari H, Doncel GF, Borenstein R. (2021). Ginkgolic Acid Inhibits Coronavirus Strain 229E Infection of Human Epithelial Lung Cells. Pharmaceuticals (Basel, Switzerland), 14(10)

Sausen DG, Bhutta MS, Gallo ES, Dahari H, Borenstein R. (2021). Stress-Induced Epstein-Barr Virus Reactivation. Biomolecules, 11(9)

Kadelka S, Dahari H, Ciupe SM. (2021). Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Scientific reports, 11(1)

Shekhtman L, Navasa M, Sansone N, Crespo G, Subramanya G, Chung TL, Cardozo-Ojeda EF, Pérez-Del-Pulgar S, Perelson AS, Cotler SJ, Forns X, Uprichard SL, Dahari H. (2021). Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. eLife, (10)

Dahari H, Shlomai A, Cotler SJ. (2021). Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed. Journal of viral hepatitis

Zakh R, Churkin A, Bietsch W, Lachiany M, Cotler SJ, Ploss A, Dahari H, Barash D. (2021). A Mathematical Model for early HBV and -HDV Kinetics during Anti-HDV Treatment. Mathematics (Basel, Switzerland), 9(24)

Zakh R, Churkin A, Totzeck F, Parr M, Tuller T, Etzion O, Dahari H, Roggendorf M, Frishman D, Barash D. (2021). A Mathematical Analysis of HDV Genotypes: From Molecules to Cells. Mathematics (Basel, Switzerland), 9(17)

Churkin A, Reinharz V, Lewkiewicz S, Dahari H, Barash D. (2020). HCVMultiscaleFit: A Simulator For Parameter Estimation in Multiscale Models Of Hepatitis C Virus Dynamics. AIP conference proceedings, (2293)

Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N, Keren-Naus A, Shemer-Avni Y, Mor O, Murad J, Novack V, Shlomai A. (2020). Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific reports, 10(1)

Chertow DS, Shekhtman L, Lurie Y, Davey RT, Heller T, Dahari H. (2020). Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment. Viruses, 12(1)

Dahari H, Vaillant A, Cotler SJ. (2020). Letter to the Editor: Examining HBV RNA kinetics during NA treatment - are NA multifunctional antiviral agents?. Hepatology (Baltimore, Md.)

Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. (2020). Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. The lancet. Gastroenterology & hepatology, 5(7)

Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. (2020). Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Scientific reports, 10(1)

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y. (2019). Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PloS one, 14(1)

Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H. (2019). Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine, 37(19)

Lhomme S, DebRoy S, Kamar N, Abravanel F, Metsu D, Marion O, Dimeglio C, Cotler SJ, Izopet J, Dahari H. (2019). Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses, 11(7)

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Eliav MC, Skorochod Y, Breuer GS, Tur-Kaspa R, Wiener YW, Stern A, Cotler SJ, Dahari H, Lurie Y. (2019). Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PloS one, 14(2)

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. (2019). A Randomized, Proof-Of-Concept Clinical Trial on Repurposing Chlorcyclizine for the Treatment of Chronic Hepatitis C. Antiviral research, (163)

Tatara E, Collier NT, Ozik J, Gutfraind A, Cotler SJ, Dahari H, Major M, Boodram B. (2019). MULTI-OBJECTIVE MODEL EXPLORATION OF HEPATITIS C ELIMINATION IN AN AGENT-BASED MODEL OF PEOPLE WHO INJECT DRUGS. Proceedings of the ... Winter Simulation Conference. Winter Simulation Conference, (2019)

Reinharz V, Dahari H, Barash D. (2018). Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics. Mathematical biosciences, (300)

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H. (2018). Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Science translational medicine, 10(449)

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H. (2019). Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver international : official journal of the International Association for the Study of the Liver, 39(5)

Dahari H, Boodram B. (2018). How to eliminate HCV in people who inject drugs in the USA. The Lancet. Infectious diseases, 18(2)

Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. (2018). High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. Journal of urban health : bulletin of the New York Academy of Medicine, 95(1)

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K. (2017). HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PloS one, 12(12)

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H. (2017). Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral research, (144)

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. (2017). Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology communications, 1(4)

Reinharz V, Churkin A, Dahari H, Barash D. (2017). A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics. Frontiers in applied mathematics and statistics, (3)

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P. (2016). HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. Journal of hepatology, 64(6)

Dahari H, Cotler SJ, Feld JJ. (2016). Cure prevents more than transmission of hepatitis C virus. Hepatology (Baltimore, Md.), 64(3)

Dahari H, Halfon P, Cotler SJ. (2016). Resurrection of response-guided therapy for sofosbuvir combination therapies. Journal of hepatology, 65(3)

Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME. (2015). Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. PlOS One, 10(9)

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H. (2015). Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. PLoS One, 10(8)

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H. (2015). Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of virology, 89(13)

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E, Lurie Y. (2015). Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver international : official journal of the International Association for the Study of the Liver, 35(2)

Dahari H, Cotler SJ. (2014). Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach. Hepatology (Baltimore, Md.), 59(6)

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H. (2014). Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antiviral therapy, 20(2)

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H. (2014). Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (Baltimore, Md.), 60(6)

Guedj J, Canini L, Cotler S, Dahari H. (2015). Reply: To PMID 25098971. Hepatology (Baltimore, Md.), 61(6)

Zhang J, Lipton HL, Perelson AS, Dahari H. (2013). Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. Journal of virology, 87(7)

Dahari H, Cotler SJ, Layden TJ, Perelson AS. (2013). Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. Journal of hepatology, 58(4)

Dahari H, Guedj J, Perelson AS. (2011). Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology (Baltimore, Md.), 54(2)

Dahari H, Guedj J, Perelson AS, Layden TJ. (2011). Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Current hepatitis reports, 10(3)

Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU. (2010). Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. Journal of hepatology, 53(3)

Dahari H, Feinstone SM, Major ME. (2010). Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology, 139(3)

Dahari H, Cotler SJ, Layden TJ, Perelson AS. (2009). Hepatitis B virus clearance rate estimates. Hepatology (Baltimore, Md.), 49(5)

Burg D, Rong L, Neumann AU, Dahari H. (2009). Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. Journal of theoretical biology, 259(4)

Dahari H, Sainz B Jr., Perelson AS, Uprichard SL. (2009). Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. Journal of virology, 83(13)

Dahari H, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, Perelson AS. (2009). A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology, 136(4)

Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. (2009). Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antiviral therapy, 14(3)

Dahari H, Shudo E, Ribeiro RM, Perelson AS. (2009). Mathematical modeling of HCV infection and treatment. Methods in molecular biology (Clifton, N.J.), (510)

Dahari H, Shudo E, Ribeiro RM, Perelson AS. (2009). Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology (Baltimore, Md.), 49(1)

Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. (2008). Hepatitis C Viral Kinetics in Special Populations. Current hepatitis reports, 7(3)

Dahari H, Ribeiro RM, Perelson AS. (2007). Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (Baltimore, Md.), 46(1)

Dahari H, Lo A, Ribeiro RM, Perelson AS. (2007). Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. Journal of theoretical biology, 247(2)

Dahari H, Perelson AS. (2007). Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology (Baltimore, Md.), 46(6)

Dahari H, Perelson AS. (2007). Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World journal of gastroenterology, 13(21)

Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH. (2007). Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of hepatology, 47(1)

Dahari H, Ribeiro RM, Rice CM, Perelson AS. (2007). Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. Journal of virology, 81(2)

Dahari H, Forns X, Neumann AU, Perelson AS. (2006). The extrahepatic contribution to HCV plasma viremia. Journal of hepatology, 45(4)

Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. (2005). Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. Journal of hepatology, 42(4)

Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. (2005). Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology, 128(4)

If you’d like to update your profile, please email modifications to questions@midasnetwork.us.

This site is registered on wpml.org as a development site.